Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment. / (Record no. 1201)

MARC details
000 -LEADER
fixed length control field 04347naa a22005777i 4500
001 - CONTROL NUMBER
control field UMUN-OA-20261005-MLS-059
003 - CONTROL NUMBER IDENTIFIER
control field local
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20261005174906.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr||||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 261005s2024 xx o u000 0 eng d
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.32604/or.2024.050350
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (local)EuropePMC:PMC11209743
040 ## - CATALOGING SOURCE
Original cataloging agency local
Language of cataloging eng
Transcribing agency local
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Paulina Chmiel
Relator term author.
245 10 - TITLE STATEMENT
Title Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment. /
Statement of responsibility, etc. Paulina Chmiel; Aleksandra SłOWIKOWSKA; Łukasz Banaszek [and others].
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture [Place of publication not identified] :
Name of producer, publisher, distributor, manufacturer Tech Science Press,
Date of production, publication, distribution, manufacture, or copyright notice 2024.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (1 article).
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
500 ## - GENERAL NOTE
General note Publication type: Review article.
500 ## - GENERAL NOTE
General note Linked open-access copy: published version.
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open access; no subscription required for the linked open-access version.
Standardized terminology for access restriction Unrestricted online access
Source of term star
520 3# - SUMMARY, ETC.
Summary, etc. Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons Attribution. See the linked licence for the applicable terms.
Uniform Resource Identifier <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>
546 ## - LANGUAGE NOTE
Language note In English.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 ## - LOCAL NOTE (RLIN)
Local note Course allocation: B. Sc. Medical Laboratory Science.
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Anaplastic Lymphoma Kinase (Alk)
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Inflammatory Myofibroblastic Tumor (Imt)
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Tyrosine Kinase Inhibitors (Tki)
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Epithelioid Inflammatory Myofibroblastic Sarcoma
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term B. Sc. Medical Laboratory Science
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term UMUN open access collection
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term molecular diagnostics
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Review articles.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Aleksandra SłOWIKOWSKA
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Łukasz Banaszek
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Anna Szumera-CIEćKIEWICZ
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name BARTłOMIEJ Szostakowski
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Mateusz J SPAłEK
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Tomasz Świtaj
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Piotr Rutkowski
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Anna M Czarnecka
Relator term author.
773 0# - HOST ITEM ENTRY
Title Oncology research
Related parts Vol. 32, no. 7, (2024), pages/article 1141-1162
International Standard Serial Number 0965-0407
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://europepmc.org/articles/PMC11209743">https://europepmc.org/articles/PMC11209743</a>
Link text Read open-access publication
Public note Open access.
Access status 0
884 ## - DESCRIPTION CONVERSION INFORMATION
Conversion process Course selection and automated MARC21 enrichment from Europe PMC metadata.
Conversion date 20261005
Identifier of source metadata https://europepmc.org/articles/PMC11209743
Conversion agency local
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC No

No items available.